Abstract
Pituitary apoplexy (PA), defined by the occurrence of a massive hemorrhagic necrotic rearrangement within a pituitary adenoma, is rare. Its occurrence can be associated with certain risk factors, including anticoagulation. We report the first case of PA with rivaroxaban which is one of the new oral anticoagulants: a 73 year-old patient presenting with severe headache and visual field deterioration. Surgery was performed. Radiotherapy treatment was decided three months after surgery because of tumor residue.
References
Chatterjee S, Sardar P, Biondi-Zoccai G, Kumbhani D (2013) New oral anticoagulants and the risk of intracranial hemorrhage: traditional and Bayesian meta-analysis and mixed treatment comparison of randomized trials of new oral anticoagulants in atrial fibrillation. JAMA Neurol 70(12):1486–1490
Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361(12):1139–1151
Uemura M, Miyashita F, Shimomura R, Fujinami J, Toyoda K (2013) Pituitary apoplexy during treatment with dabigatran. Neurol Clin Neurosci 1:82–83
Doglietto F, Costi E, Villaret AB, Mardighian D, Fontanella MM, Giustina A (2016) New oral anticoagulants and pituitary apoplexy. Pituitary 19(2):232‑4
Doglietto F, Roca E, La Rocca G, Schreiber A, Bolzoni Villaret A, Nicolai P et al (2017) New oral anticoagulants and pituitary apoplexy. World Neurosurg 100:700
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ly, S., Naman, A., Chaufour-Higel, B. et al. Pituitary apoplexy and rivaroxaban. Pituitary 20, 709–710 (2017). https://doi.org/10.1007/s11102-017-0828-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11102-017-0828-4